In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity

Leukemia

Volumn 15, Issue 6, 2001, Pages 921-928

  Wuchter, C ^a   Krappmann, D ^b   Cai, Z ^c   Ruppert, V ^a   Scheidereit, C ^b   Dorken B ^a   Ludwig, W D ^a   Karawajew, L ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute leukemia; Apoptosis; NF B; TRAIL; TRAIL receptors R1 R4

Indexed keywords

CELL RECEPTOR; CYTOKINE RECEPTOR; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER THERAPY; CELL CULTURE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SENSITIVITY; ELECTROPHORETIC MOBILITY; EVALUATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SIGNAL TRANSDUCTION; STAINING; STEM CELL; T LYMPHOCYTE; TIME;

EID: 0034989624     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402131     Document Type: Article

References (55)

1. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies
2. Induction of apoptosis by cancer chemotherapy
3. Apoptosis and drug response
4. Apoptosis control by death and decoy receptors
5. TRAIL: A molecule with multiple receptors and control mechanisms
6. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
7. Safety and antitumor activity of recombinant soluble Apo2 ligand
8. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
9. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
10. Molecular determinants of response to TRAIL in killing of normal and cancer cells
11. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
12. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
13. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
14. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis
15. Death and decoy receptors and p53-mediated apoptosis
16. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
17. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells
18. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies
19. Apoptosis-induced by trail and TNF-alpha in human multiple myeloma cells is not blocked by bcl-2
20. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
21. Functional expression of TRAIL by lymphoid and myeloid tumour cells
22. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation
23. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
24. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages
25. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
26. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
27. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells
28. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
29. Proposed revised criteria for the classification of acute myeloid leukemia
30. Proposals for the immunological classification of acute leukemias
31. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias
32. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87
33. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials. GMALL 03/87 and 04/89
34. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells
35. Clinical significance of CD95, Bcl-2 and Bax expression in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturational stage, and cytogenetics
36. Inhibition of in vitro spontaneous apoptosis by II-7 correlates with upregulation of Bcl-2, cortical/mature phenotype, and better early cytoreduction in childhood T-ALL
37. Cell death beyond apoptosis
38. Transcription factor NF-kappa B is constitutively activated in acute lymphoblastic leukemia cells
39. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict response to induction chemotherapy and relapse rate in childhood ALL
40. TRAIL/Apo-2-ligand-induced apoptosis in human T cells
41. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways
42. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
43. Functional analysis of TRAIL receptors using monoclonal antibodies
44. Reconstitution of caspase-8 sensitizes JB6 cells to TRAIL
45. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2-or Bcl-x(L)-overexpressing chemotherapy-resistant tumor cells
46. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
47. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis
48. Dissecting the pathways to death
49. The NF-kappa B/Rel and I kappa B gene families: Mediators of immune response and inflammation
50. Rel/NF-kappa B and I kappa B factors in oncogenesis
51. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
52. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death
53. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
54. TRAIL induces apoptosis and activation of NFkappaB
55. Regulation of NF-kappa B activity by I kappa B alpha and I kappa B beta stability